series-b
Stage
1
Investors
About
Ribometrix develops small-molecule drugs targeting structured RNA using a proprietary platform that maps RNA structures to identify RNA-targeting ligands for therapeutic purposes.
Explore Ribometrix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.